Loading company…
NewAmsterdam Pharma develops treatments for cardiovascular disease and lipid disorders.
Founded in 2019 and based in Naarden, Netherlands, NewAmsterdam Pharma develops treatments for cardiovascular disease and lipid disorders. Its lead product, obicetrapib, is designed to lower LDL-C levels by inhibiting CETP. The company reported revenue of USD 14.09 mn in 2023 and raised USD 235.00 mn in a merger transaction.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in